mTOR Inhibition for Cancer Therapy: Past, Present and Future

  • Monica Mita
  • Alain Mita
  • Eric K. Rowinsky

Table of contents

  1. Front Matter
    Pages i-vi
  2. Hala Elnakat Thomas, Sónia R. Pereira da Veiga, George Thomas, Sara C. Kozma
    Pages 19-45
  3. Carlyn C. Tan, Robert A. Figlin, Andrew E. Hendifar
    Pages 47-66
  4. Philippe G. Aftimos, Martine J. Piccart-Gebhart
    Pages 67-92
  5. Andrew E. Hendifar, Sandy Liu, Edward Wolin
    Pages 93-112
  6. Gaurav Shah, Sotirios Stergiopoulos, David Lebwohl
    Pages 113-137
  7. Derrick W. Su, Monica Mita, Alain C. Mita
    Pages 161-189
  8. Jesus Garcia-Donas, Juan Francisco Rodriguez-Moreno, Nuria Romero-Laorden, Manuel Hidalgo
    Pages 191-215
  9. Sandrine Faivre, Cindy Neuzillet, Eric Raymond
    Pages 217-228
  10. Ben Markman, Violeta Serra, Josep Tabernero
    Pages 251-275
  11. Zelton Dave Sharp, Paul Hasty
    Pages 277-292
  12. Back Matter
    Pages 293-300

About this book

Introduction

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

Keywords

Akt cancer mTOR rapamycin

Editors and affiliations

  • Monica Mita
    • 1
  • Alain Mita
    • 2
  • Eric K. Rowinsky
    • 3
  1. 1.Samuel Oschin Comprehensive Cancer Inst Cedars Sinai Medical CenterLos AngelesUSA
  2. 2.Samuel Oschin Comprehensive Cancer Inst Cedars-Sinai Medical CenterLos AngelesUSA
  3. 3.Stemline Therapeutics, Inc.New YorkUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-2-8178-0492-7
  • Copyright Information Springer-Verlag France 2016
  • Publisher Name Springer, Paris
  • eBook Packages Medicine
  • Print ISBN 978-2-8178-0491-0
  • Online ISBN 978-2-8178-0492-7
  • About this book
Industry Sectors
Biotechnology
Pharma